Request Your Free White Paper Now:

"Improving clinical outcomes in wound care with early use of enzymatic debridement"

Download this free whitepaper to learn more.

Chronic wounds represent a major challenge for patient care and healthcare economics, with annual costs estimated at $33 billion. Delays in effective debridement contribute to protracted healing times and increased complications.

This whitepaper provides a detailed analysis of real-world data exploring the impact of initiating Collagenase SANTYL™ Ointment treatment during the initial inpatient phase.

This whitepaper covers:

• Clinical Trajectory: An analysis of over 15,000 patient records.
• Biological Role of Collagenase: An exploration of the unique, wound-modulating properties of Clostridium collagenase.
• Cost-Effectiveness Data: Quantitative analysis revealing the association between early treatment initiation and reduced overall healthcare costs.

Download the whitepaper to explore these data-driven strategies for enhancing patient outcomes and operational efficiency in chronic wound management.

 

SANTYL Indications and Important Safety Information
Collagenase SANTYL Ointment (“SANTYL”) is a prescription-only medication indicated for debriding chronic dermal ulcers and severely burned areas. Contraindications: SANTYL is contraindicated in patients who have shown local or systemic hypersensitivity to collagenase. Warning and Precautions: The optimal pH range of collagenase is 6 to 8. Higher or lower pH conditions will decrease the enzyme’s activity and appropriate precautions should be taken. The enzymatic activity is also adversely affected by certain detergents, and heavy metal ions such as mercury and silver which are used in some antiseptics. As such, the wound should be properly cleansed prior to application of SANTYL. Debilitated patients should be closely monitored for systemic bacterial infections because of the theoretical possibility that debriding enzymes may increase the risk of bacteremia. A slight transient erythema has been noted occasionally in the surrounding tissue, particularly when SANTYL was not confined to the wound. SANTYL is not indicated for wound closure. Discontinue use of SANTYL after granulation tissue is well-established. Adverse Reactions: No allergic sensitivity or toxic reactions have been noted in clinical use when used as directed. The risk information provided herein is not comprehensive. For complete prescribing information, please refer to the accompanying PI or visit: https://santyl.com/sites/default/files/2019-12/SANTYL-PI.pdf. You are encouraged to report negative side effects of prescription drugs to FDA. Visit MedWatch or call 1-800-FDA-1088.

 

SAME68-46552-1225

Offered Free by: Smith & Nephew
See All Resources from: Smith & Nephew